Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Apellis Pharmaceuticals, Inc. (APLS) reported $458.58 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 133%. EPS of$ 1.67 for the same period compares to - $0.46 a year ago.The reported revenue represents a surprise of +25.22% over the Zacks Consensus Estimate of$ 366.21 million. With the consensus EPS estimate being $1.03, the EPS surprise was +62.14%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...